PRL phosphatases as potential molecular targets in cancer

Bret J. Stephens, Haiyong Han, Vijay Gokhale, Daniel D. Von Hoff

Research output: Contribution to journalArticle

133 Citations (Scopus)

Abstract

The phosphatase of regenerating liver (PRL) family of phosphatases, consisting of PRL-1, PRL-2, and PRL-3, represents an intriguing group of proteins being validated as biomarkers and therapeutic targets in cancer. Individual PRLs are overexpressed in a variety of cancer cell lines and tissues when compared with their normal counterparts. More importantly, several recent studies have shown that PRL-3 is expressed at higher levels and at a greater frequency in colorectal cancer metastases compared with primary colorectal tumors and normal colon tissue. Ectopic expression of PRLs in nontumorigenic cells can influence proliferation and the migratory and invasive properties of cells, while knockdown of endogenous PRL-3 or PRL-1 in cancerous cells using small interfering RNA can abrogate cell motility and ability to metastasize in a mouse model. However, the exact biological function and cellular substrates of the PRLs remain unclear. This review will discuss what is known about the PRLs, what makes the PRLs possible attractive targets for therapeutic intervention, and the possible future directions in PRL biology and inhibitor identification.

Original languageEnglish (US)
Pages (from-to)1653-1661
Number of pages9
JournalMolecular Cancer Therapeutics
Volume4
Issue number11
DOIs
StatePublished - Nov 2005

Fingerprint

Phosphoric Monoester Hydrolases
Liver
Neoplasms
Colorectal Neoplasms
Small Interfering RNA
Cell Movement
Colon
Biomarkers
Neoplasm Metastasis
Cell Line
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Pharmacology

Cite this

PRL phosphatases as potential molecular targets in cancer. / Stephens, Bret J.; Han, Haiyong; Gokhale, Vijay; Von Hoff, Daniel D.

In: Molecular Cancer Therapeutics, Vol. 4, No. 11, 11.2005, p. 1653-1661.

Research output: Contribution to journalArticle

Stephens, Bret J. ; Han, Haiyong ; Gokhale, Vijay ; Von Hoff, Daniel D. / PRL phosphatases as potential molecular targets in cancer. In: Molecular Cancer Therapeutics. 2005 ; Vol. 4, No. 11. pp. 1653-1661.
@article{fa429314e065489ca8db2af420768772,
title = "PRL phosphatases as potential molecular targets in cancer",
abstract = "The phosphatase of regenerating liver (PRL) family of phosphatases, consisting of PRL-1, PRL-2, and PRL-3, represents an intriguing group of proteins being validated as biomarkers and therapeutic targets in cancer. Individual PRLs are overexpressed in a variety of cancer cell lines and tissues when compared with their normal counterparts. More importantly, several recent studies have shown that PRL-3 is expressed at higher levels and at a greater frequency in colorectal cancer metastases compared with primary colorectal tumors and normal colon tissue. Ectopic expression of PRLs in nontumorigenic cells can influence proliferation and the migratory and invasive properties of cells, while knockdown of endogenous PRL-3 or PRL-1 in cancerous cells using small interfering RNA can abrogate cell motility and ability to metastasize in a mouse model. However, the exact biological function and cellular substrates of the PRLs remain unclear. This review will discuss what is known about the PRLs, what makes the PRLs possible attractive targets for therapeutic intervention, and the possible future directions in PRL biology and inhibitor identification.",
author = "Stephens, {Bret J.} and Haiyong Han and Vijay Gokhale and {Von Hoff}, {Daniel D.}",
year = "2005",
month = "11",
doi = "10.1158/1535-7163.MCT-05-0248",
language = "English (US)",
volume = "4",
pages = "1653--1661",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - PRL phosphatases as potential molecular targets in cancer

AU - Stephens, Bret J.

AU - Han, Haiyong

AU - Gokhale, Vijay

AU - Von Hoff, Daniel D.

PY - 2005/11

Y1 - 2005/11

N2 - The phosphatase of regenerating liver (PRL) family of phosphatases, consisting of PRL-1, PRL-2, and PRL-3, represents an intriguing group of proteins being validated as biomarkers and therapeutic targets in cancer. Individual PRLs are overexpressed in a variety of cancer cell lines and tissues when compared with their normal counterparts. More importantly, several recent studies have shown that PRL-3 is expressed at higher levels and at a greater frequency in colorectal cancer metastases compared with primary colorectal tumors and normal colon tissue. Ectopic expression of PRLs in nontumorigenic cells can influence proliferation and the migratory and invasive properties of cells, while knockdown of endogenous PRL-3 or PRL-1 in cancerous cells using small interfering RNA can abrogate cell motility and ability to metastasize in a mouse model. However, the exact biological function and cellular substrates of the PRLs remain unclear. This review will discuss what is known about the PRLs, what makes the PRLs possible attractive targets for therapeutic intervention, and the possible future directions in PRL biology and inhibitor identification.

AB - The phosphatase of regenerating liver (PRL) family of phosphatases, consisting of PRL-1, PRL-2, and PRL-3, represents an intriguing group of proteins being validated as biomarkers and therapeutic targets in cancer. Individual PRLs are overexpressed in a variety of cancer cell lines and tissues when compared with their normal counterparts. More importantly, several recent studies have shown that PRL-3 is expressed at higher levels and at a greater frequency in colorectal cancer metastases compared with primary colorectal tumors and normal colon tissue. Ectopic expression of PRLs in nontumorigenic cells can influence proliferation and the migratory and invasive properties of cells, while knockdown of endogenous PRL-3 or PRL-1 in cancerous cells using small interfering RNA can abrogate cell motility and ability to metastasize in a mouse model. However, the exact biological function and cellular substrates of the PRLs remain unclear. This review will discuss what is known about the PRLs, what makes the PRLs possible attractive targets for therapeutic intervention, and the possible future directions in PRL biology and inhibitor identification.

UR - http://www.scopus.com/inward/record.url?scp=28044448270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28044448270&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-05-0248

DO - 10.1158/1535-7163.MCT-05-0248

M3 - Article

C2 - 16275986

AN - SCOPUS:28044448270

VL - 4

SP - 1653

EP - 1661

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 11

ER -